OBJECTIVE: This article describes the establishment of a research pharmacy to support the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) vaccine study for Ebola virus disease. SETTING: This article describes the establishment of the pharmacy element to support the overall research program during an Ebola outbreak in Monrovia, Liberia, in 2014 and 2015. PRACTICE INNOVATION: The need for the rapid establishment of infrastructure to support the Liberia-United States joint clinical research partnership in response to the emerging Ebola virus disease provided the opportunity for collaboration among Liberian and U.S. pharmacists. PRACTICE DESCRIPTION: Resource austere and research naïve. EVALUATION: Research pharmacy prepared and randomized 1500 vaccinations in support of PREVAIL. RESULTS: Experiences of the Liberian and U.S. pharmacists involved in the program are described. CONCLUSION: The partnership was successful in the conduct of the study. More importantly, the capacity for Liberian pharmacists to support clinical research was established. In addition, the U.S. team learned several important lessons that will help prepare them for responding to research needs in future infectious disease outbreaks. Published by Elsevier Inc.
OBJECTIVE: This article describes the establishment of a research pharmacy to support the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) vaccine study for Ebola virus disease. SETTING: This article describes the establishment of the pharmacy element to support the overall research program during an Ebola outbreak in Monrovia, Liberia, in 2014 and 2015. PRACTICE INNOVATION: The need for the rapid establishment of infrastructure to support the Liberia-United States joint clinical research partnership in response to the emerging Ebola virus disease provided the opportunity for collaboration among Liberian and U.S. pharmacists. PRACTICE DESCRIPTION: Resource austere and research naïve. EVALUATION: Research pharmacy prepared and randomized 1500 vaccinations in support of PREVAIL. RESULTS: Experiences of the Liberian and U.S. pharmacists involved in the program are described. CONCLUSION: The partnership was successful in the conduct of the study. More importantly, the capacity for Liberian pharmacists to support clinical research was established. In addition, the U.S. team learned several important lessons that will help prepare them for responding to research needs in future infectious disease outbreaks. Published by Elsevier Inc.
Authors: Mamoudou H Djingarey; Rodrigue Barry; Mete Bonkoungou; Sylvestre Tiendrebeogo; Rene Sebgo; Denis Kandolo; Clement Lingani; Marie-Pierre Preziosi; Patrick L F Zuber; William Perea; Stéphane Hugonnet; Nora Dellepiane de Rey Tolve; Carole Tevi-Benissan; Thomas A Clark; Leonard W Mayer; Ryan Novak; Nancy E Messonier; Monique Berlier; Desire Toboe; Deo Nshimirimana; Richard Mihigo; Teresa Aguado; Fabien Diomandé; Paul A Kristiansen; Dominique A Caugant; F Marc Laforce Journal: Vaccine Date: 2012-05-30 Impact factor: 3.641
Authors: Stephen B Kennedy; James D Neaton; H Clifford Lane; Mark W S Kieh; Moses B F Massaquoi; Nancy A Touchette; Martha C Nason; Dean A Follmann; Fatorma K Boley; Melvin P Johnson; Gregg Larson; Francis N Kateh; Tolbert G Nyenswah Journal: Clin Trials Date: 2016-01-14 Impact factor: 2.486